DE69836219D1 - Verwendung von herpes-vektoren zur tumortherapie - Google Patents
Verwendung von herpes-vektoren zur tumortherapieInfo
- Publication number
- DE69836219D1 DE69836219D1 DE69836219T DE69836219T DE69836219D1 DE 69836219 D1 DE69836219 D1 DE 69836219D1 DE 69836219 T DE69836219 T DE 69836219T DE 69836219 T DE69836219 T DE 69836219T DE 69836219 D1 DE69836219 D1 DE 69836219D1
- Authority
- DE
- Germany
- Prior art keywords
- tumor
- cells
- patient
- immune response
- cell type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5514297P | 1997-08-12 | 1997-08-12 | |
US55142P | 1997-08-12 | ||
US64174 | 1998-04-22 | ||
US09/064,174 US6379674B1 (en) | 1997-08-12 | 1998-04-22 | Use of herpes vectors for tumor therapy |
PCT/US1998/016447 WO1999007394A1 (en) | 1997-08-12 | 1998-08-12 | Use of herpes vectors for tumor therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69836219D1 true DE69836219D1 (de) | 2006-11-30 |
DE69836219T2 DE69836219T2 (de) | 2007-08-23 |
Family
ID=26733894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69836219T Expired - Lifetime DE69836219T2 (de) | 1997-08-12 | 1998-08-12 | Verwendung von herpes-vektoren zur tumortherapie |
Country Status (12)
Country | Link |
---|---|
US (5) | US6379674B1 (de) |
EP (2) | EP1003533B1 (de) |
JP (2) | JP5078195B2 (de) |
AT (1) | ATE342724T1 (de) |
AU (1) | AU8824998A (de) |
CA (1) | CA2301327C (de) |
DE (1) | DE69836219T2 (de) |
ES (2) | ES2627764T3 (de) |
HK (1) | HK1028560A1 (de) |
LU (1) | LUC00032I2 (de) |
PT (1) | PT1776957T (de) |
WO (1) | WO1999007394A1 (de) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
CA2356937A1 (en) * | 1998-12-31 | 2000-07-13 | Richard J. Whitley | Recombinant herpes simplex virus useful for treating neoplastic disease |
US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
EP1190040B1 (de) * | 1999-06-08 | 2007-08-22 | UAB Research Foundation | Herpes-simplex virus, das das gen von interleukin-12 exprimiert, und dessen verwendung zur behandlung von krebs |
US6723316B2 (en) * | 1999-12-22 | 2004-04-20 | Onyx Pharmaceuticals, Inc. | Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth |
ES2233600T5 (es) | 2000-01-21 | 2009-06-22 | Biovex Limited | Cepas de virus del herpes. |
WO2002076216A1 (en) | 2001-03-27 | 2002-10-03 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
JP2004529158A (ja) * | 2001-05-02 | 2004-09-24 | ラモツト・アツト・テル−アビブ・ユニバーシテイ・リミテツド | 混成殺腫瘍ヘルペスウイルスベクター |
DE10131148A1 (de) * | 2001-06-28 | 2003-01-16 | I P L Internat Pharmaceutics L | Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren |
AU2003216502B2 (en) * | 2002-03-01 | 2008-04-10 | Sloan-Kettering Institute For Cancer Research | Prevention of recurrence and metastasis of cancer |
JP2004099584A (ja) * | 2002-05-02 | 2004-04-02 | Keio Gijuku | Hsvを用いた抗腫瘍剤 |
US8216564B2 (en) * | 2002-05-02 | 2012-07-10 | Ramot At Tel-Aviv University Ltd. | Composite oncolytic herpes virus vectors |
WO2005094867A1 (ja) * | 2004-03-31 | 2005-10-13 | Tomoki Todo | ウイルス療法の抗癌作用増強剤、癌の予防または治療方法 |
WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
WO2009052426A2 (en) * | 2007-10-17 | 2009-04-23 | The Ohio State University | Oncolytic virus |
US8450106B2 (en) * | 2007-10-17 | 2013-05-28 | The Ohio State University Research Foundation | Oncolytic virus |
KR100905419B1 (ko) | 2008-09-11 | 2009-07-02 | 연세대학교 산학협력단 | 세스퀴테르펜 유도체의 용도 |
EP2687609B1 (de) | 2008-11-10 | 2017-01-04 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Behandlung von soliden Tumoren |
US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
LT2753355T (lt) * | 2011-09-08 | 2019-01-25 | New York University | Onkolitinis herpes simplex virusas ir jo terapinis panaudojimas |
CA2971201A1 (en) | 2014-12-18 | 2016-06-23 | Amgen Inc. | Stable frozen herpes simplex virus formulation |
WO2016205429A1 (en) | 2015-06-15 | 2016-12-22 | New York University | Method of treatment using oncolytic viruses |
WO2017013421A1 (en) | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
SG11201805835WA (en) | 2016-01-08 | 2018-08-30 | Replimune Ltd | Modified oncolytic virus |
US20190336552A1 (en) | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
JP6794442B2 (ja) * | 2016-05-30 | 2020-12-02 | アステラス製薬株式会社 | 新規な遺伝子組換えワクシニアウイルス |
JP7200104B2 (ja) * | 2016-08-01 | 2023-01-06 | ヴァイロジン バイオテック カナダ リミテッド | 免疫系刺激分子を発現する腫瘍溶解性単純ヘルペスウイルスベクター |
CN110461346A (zh) | 2017-03-15 | 2019-11-15 | 美国安进公司 | 溶瘤病毒单独或与检查点抑制剂组合用于治疗癌症的用途 |
EP3661954B1 (de) | 2017-08-03 | 2022-02-09 | Amgen Inc. | Interleukin-21-muteine und verfahren zur behandlung |
TW201912173A (zh) | 2017-08-07 | 2019-04-01 | 美商安進公司 | 三陰性乳癌或結腸直腸癌伴隨肝轉移之治療 |
ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
CR20210319A (es) | 2018-01-12 | 2021-07-27 | Amgen Inc | ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330) |
CN108635380A (zh) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 |
SG11202103097QA (en) | 2018-09-26 | 2021-04-29 | Astellas Pharma Inc | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
TW202039835A (zh) | 2018-12-27 | 2020-11-01 | 美商安進公司 | 凍乾病毒配製物 |
BR112021017551A2 (pt) | 2019-03-05 | 2021-11-09 | Amgen Inc | Uso de vírus oncolíticos para o tratamento de câncer |
TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
BR112023020209A2 (pt) | 2021-04-02 | 2023-12-19 | Krystal Biotech Inc | Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9001828A (nl) | 1990-08-15 | 1992-03-02 | Centraal Diergeneeskundig Inst | Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde. |
EP0573564A1 (de) | 1991-02-22 | 1993-12-15 | Massachusetts Institute Of Technology | Nestinexpression als indikator für neuroepithel-tumore |
JP3974167B2 (ja) * | 1992-03-31 | 2007-09-12 | アーチ デベロプメント コーポレイション | 遺伝子,腫瘍及びウイルス感染の治療,並びにプログラムされた細胞死(アポプトーシス)を予防するための方法及び組成物 |
US5639656A (en) * | 1994-03-31 | 1997-06-17 | Medical College Of Hampton Road | Antibodies reactive with biological markers of benign prostate hyperplasia |
US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US6699468B1 (en) * | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5728379A (en) * | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
JP3822261B2 (ja) * | 1994-09-09 | 2006-09-13 | 財団法人癌研究会 | 癌の遺伝子治療剤 |
GB9511101D0 (en) | 1995-06-01 | 1995-07-26 | British Tech Group | Magnetic coil |
WO1997026904A1 (en) * | 1996-01-25 | 1997-07-31 | Medical Research Council | Treatment of non-neuronal cancer using hsv mutant |
US6051428A (en) * | 1997-03-21 | 2000-04-18 | Sloan-Kettering Institute For Cancer Research | Rapid production of autologous tumor vaccines |
US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
WO2002076216A1 (en) * | 2001-03-27 | 2002-10-03 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
-
1998
- 1998-04-22 US US09/064,174 patent/US6379674B1/en not_active Expired - Fee Related
- 1998-08-12 ES ES06021697.5T patent/ES2627764T3/es not_active Expired - Lifetime
- 1998-08-12 AT AT98939886T patent/ATE342724T1/de active
- 1998-08-12 PT PT60216975T patent/PT1776957T/pt unknown
- 1998-08-12 DE DE69836219T patent/DE69836219T2/de not_active Expired - Lifetime
- 1998-08-12 JP JP2000506984A patent/JP5078195B2/ja not_active Expired - Lifetime
- 1998-08-12 ES ES98939886T patent/ES2276470T3/es not_active Expired - Lifetime
- 1998-08-12 EP EP98939886A patent/EP1003533B1/de not_active Revoked
- 1998-08-12 AU AU88249/98A patent/AU8824998A/en not_active Abandoned
- 1998-08-12 EP EP06021697.5A patent/EP1776957B1/de not_active Expired - Lifetime
- 1998-08-12 CA CA2301327A patent/CA2301327C/en not_active Expired - Lifetime
- 1998-08-12 WO PCT/US1998/016447 patent/WO1999007394A1/en active IP Right Grant
-
2000
- 2000-11-30 HK HK00107700A patent/HK1028560A1/xx not_active IP Right Cessation
-
2002
- 2002-02-22 US US10/079,534 patent/US20020127246A1/en not_active Abandoned
-
2005
- 2005-04-04 US US11/097,391 patent/US20050232907A1/en not_active Abandoned
-
2008
- 2008-08-20 US US12/194,872 patent/US8361978B2/en not_active Expired - Fee Related
-
2011
- 2011-11-04 JP JP2011242601A patent/JP2012067114A/ja active Pending
-
2013
- 2013-02-15 US US13/769,182 patent/US9827307B2/en not_active Expired - Fee Related
-
2017
- 2017-08-09 LU LU00032C patent/LUC00032I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
PT1776957T (pt) | 2017-06-12 |
US20050232907A1 (en) | 2005-10-20 |
ES2276470T3 (es) | 2007-06-16 |
AU8824998A (en) | 1999-03-01 |
US20020127246A1 (en) | 2002-09-12 |
EP1776957A2 (de) | 2007-04-25 |
US9827307B2 (en) | 2017-11-28 |
JP2001513508A (ja) | 2001-09-04 |
CA2301327C (en) | 2011-06-14 |
CA2301327A1 (en) | 1999-02-18 |
US20090053178A1 (en) | 2009-02-26 |
ATE342724T1 (de) | 2006-11-15 |
EP1003533A1 (de) | 2000-05-31 |
JP2012067114A (ja) | 2012-04-05 |
DE69836219T2 (de) | 2007-08-23 |
HK1028560A1 (en) | 2001-02-23 |
EP1776957B1 (de) | 2017-03-01 |
LUC00032I2 (de) | 2017-10-11 |
US20130224243A1 (en) | 2013-08-29 |
ES2627764T3 (es) | 2017-07-31 |
LUC00032I1 (de) | 2017-08-10 |
US8361978B2 (en) | 2013-01-29 |
EP1776957A3 (de) | 2009-06-24 |
JP5078195B2 (ja) | 2012-11-21 |
US6379674B1 (en) | 2002-04-30 |
EP1003533B1 (de) | 2006-10-18 |
WO1999007394A1 (en) | 1999-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LUC00032I1 (de) | ||
FR2712603B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
DE69233186D1 (de) | Karcinoembryonale antigen expremierende rekombinante viren und methoden ihrer anwendung | |
HU9500732D0 (en) | Defective adenovirus vectors and use thereof in gene therapy | |
EP1192948A3 (de) | Verwendung einer HSV Mutante zur Behandlung von Krebs | |
AU4283389A (en) | Modified viral glycoproteins, diagnostic and therapeutic uses therefore | |
ATE308999T1 (de) | Intrazellulare expression von carboxypeptidase g2 in enzyme-prodrug-therapie | |
BR9608449A (pt) | Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica. | |
FR2707664B1 (fr) | Vecteurs viraux et utilisation en thérapie génique. | |
IL111682A0 (en) | Recombinant viruses and their use in gene therapy | |
FR2702152B1 (fr) | Virus recombinants et leur utilisation en thérapie génique. | |
AU1927797A (en) | Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines | |
CA2118724A1 (en) | Detection method for c-raf-1 genes | |
IL107378A0 (en) | Soluble interferon a-receptor, its preparation and use | |
DK0783585T3 (da) | Defekte rekombinante adenovira med et inaktiveret IVa2-gen | |
HUP9801214A2 (hu) | Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk | |
FR2717495B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
EP0876507A4 (de) | Regelung und kontrolle der expression der protein phosphatase 2c-pp2c-alpha in tumor zellen bei der tumor therapie, vorbeugung und bestimmung | |
JPS6488392A (en) | Human body position detecting device | |
IL112992A0 (en) | Recombinant viruses, their preparation and their use in gene therapy | |
FR2717823B1 (fr) | Virus recombinants, préparation et utilisation en thérapie génique. | |
NO803934L (no) | Fremgangsmaate for nedsettelse av fenylalanininnholdet i prav oteinhydrolysater, og kjoettaromakonsentrater fremstilt der | |
OUCHI | Some informal remarks on the M-form society | |
NO914094L (no) | Nytt monoklonalt antistoff mot nytt antigen forbundet medhumantumorer | |
Biela et al. | Denominational ingroup and outgroup perceptions in Poland. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |